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OBJECTIVES We sought to identify the incidence, predictors, and clinical consequences of one-month
reinfarction (RE-MI) in patients undergoing primary percutaneous coronary intervention
(PCI) for acute myocardial infarction (AMI).
BACKGROUND One-month reinfarction after AMI significantly increases long-term mortality; however, little
is known about the incidence and predictors of RE-MI in patients undergoing primary
angioplasty.
METHODS We analyzed data from 3,646 patients who underwent primary PCI in the Primary
Angioplasty in Acute Myocardial Infarction (PAMI) studies. We studied the incidence,
correlates, and clinical outcomes of 30-day RE-MI.
RESULTS Reinfarction within one month of index hospitalization occurred in 77 (2.1%) of patients. In
multivariate analysis, admission Killip class 1 (odds ratio [OR] 2.02, 95% confidence
interval [CI] 1.09 to 3.76), left ventricular ejection fraction 50% (OR 2.49, 95% CI 1.30 to
4.74), final coronary stenosis 30% (OR 2.57, 95% CI 1.28 to 5.15), and presence of
coronary dissection (OR 2.40, 95% CI 1.36 to 4.24) and thrombus (OR 2.36, 95% CI 1.23
to 4.53) on the final angiogram were independent correlates of RE-MI. One-month
reinfarction was independently associated with death (OR 7.14, 95% CI 3.28 to 15.5) and
ischemic target vessel revascularization (I-TVR) (OR 15.0, 95% CI 8.68 to 26.0) at six
months.
CONCLUSIONS We conclude that, although early RE-MI is uncommon in patients treated by primary PCI,
it is a significant independent predictor of death and I-TVR at six months. Admission Killip
class 1 and left ventricular systolic dysfunction were associated with higher incidence of
RE-MI. Our results suggest that optimal revascularization during primary PCI may decrease
RE-MI rates. (J Am Coll Cardiol 2003;42:1173–7) © 2003 by the American College of
Cardiology Foundation
Reinfarction (RE-MI) after acute myocardial infarction
(AMI) leads to increased morbidity and mortality (1–4).
Before the advent of revascularization therapy using throm-
bolytics or primary angioplasty, nearly one-quarter of all
Q-wave myocardial infarction patients suffered RE-MI
within 10 years (5). With increased use of aspirin and
beta-blockers, thrombolytic therapy led to a reduction in
one-year RE-MI rates by about 2% per year between 1987
and 1994 (4–10). Donges et al. (3) studied AMI patients
enrolled in a large registry and found that 4.7% of patients
had in-hospital RE-MI and that the incidence of RE-MI
was lower in patients treated with percutaneous coronary
intervention (PCI) compared with thrombolytics.
Little is known about RE-MI occurring early after AMI
in the era of primary angioplasty. Because primary angio-
plasty is associated with better Thrombolysis In Myocardial
Infarction (TIMI) flow in the infarct-related artery, the
incidence of RE-MI is expected to be lower than that noted
historically in thrombolytic studies. More recently, Keeley et
al. (11) performed a pooled analysis of 23 randomized trials
of PCI versus thrombolytics and found a significant de-
crease in RE-MI with PCI. We performed this analysis to
study the incidence, clinical, and angiographic predictors,
and clinical consequences of one-month RE-MI in patients
undergoing primary angioplasty.
METHODS
Study population. We analyzed data available in 3,646
patients treated by primary PCI in seven Primary Angio-
plasty in Acute Myocardial Infarction (PAMI) studies,
including PAMI-1 (12), PAMI-2 (13), Stent PAMI (14),
Local PAMI (15), Stent Pilot (10), PAMI No Surgery on
Site, and Air PAMI (16) (Table 1).
PAMI study protocol. All patients enrolled presented
within 12 h of onset of chest pain and electrocardiographic
changes (ST elevation in two contiguous leads or left bundle
branch block). The trials excluded patients presenting with
cardiogenic shock, high bleeding risk, and those who did
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not give informed consent. The protocols of all seven studies
were previously published. In brief, it was recommended
that patients receive 325-mg chewable aspirin, a 5,000- to
10,000-U bolus of heparin, intravenous beta-adrenergic
blockers, and nitroglycerin. Patients were taken emergently
to the cath lab for coronary angiography and possible
intervention. Those patients deemed unlikely to benefit
from primary PCI (infarct-related artery with 70% steno-
sis or supplying a small area of myocardium) were treated
medically without mechanical intervention. Patients found
to have unprotected left main stenosis 60% or severe
proximal three-vessel disease and spontaneous reperfusion
were referred for coronary artery bypass grafting. In the
absence of these contraindications, patients underwent PCI.
Patients undergoing PCI were given heparin to achieve an
activated clotting time between 350 and 400 s. Study
monitors recorded six-month follow-up events.
Study outcome. Reinfarction was defined as recurrence of
clinical symptoms (or new electrocardiographic changes)
and new elevation of creatine kinase (CK) or CK-MB
within 30 days after hospital admission. We compared
baseline clinical and angiographic characteristics of both
groups and assessed independent correlates of RE-MI.
Further, we evaluated the independent impact of RE-MI on
six-month ischemic target revascularization (I-TVR) and
six-month mortality.
Statistics. Statistical analyses were completed on the cate-
gorical variables using a chi-square test or a Fisher exact test
as appropriate. If the frequency of any cell was 5, then a
Fisher exact test was used. The continuous variables were
analyzed using a Wilcoxon rank test. Kaplan-Meier analysis
was used to create survival curves for the cumulative inci-
dence of death during six-month follow-up for RE-MI and
no RE-MI patients. Log-rank p test was used to compare
survival curves between RE-MI and no RE-MI groups. We
did multivariate logistic regression to determine indepen-
dent correlates of RE-MI. Clinical and angiographic vari-
ables that showed a univariate relation (p  0.10) with
RE-MI were included in the multivariate analysis. Step-
down logistic regression was performed, dropping the least
significant variable at each step, until only variables with a p
value of 0.05 remained. To determine the independent
correlation of RE-MI with death and I-TVR at six months,
we completed similar multivariate analyses. Clinical and
angiographic differences between study groups were used as
potential covariates in both models.
RESULTS
Incidence of RE-MI. Of 3,646 study patients, 77 (2.1%)
suffered one-month RE-MI. The cumulative incidence of
RE-MI within the first 30 days is shown in Figure 1.
Baseline characteristics. Clinical and angiographic differ-
ences between no RE-MI and RE-MI groups are shown in
Tables 2 and 3. Reinfarction patients had higher Killip class
at presentation and were less likely to be smokers; RE-MI
patients had lower TIMI 3 flow before and after PCI, lower
left ventricular ejection fraction (LVEF), higher percent
stenosis pre-PCI and post-PCI, higher rate of intracoronary
thrombus and coronary dissection on the final angiogram,
and lower PCI success.
Independent correlates of RE-MI. In multivariate analy-
sis, the following variables remained significant independent
correlates of RE-MI: admission Killip class 1 (odds ratio
[OR] 2.02, 95% confidence interval [CI] 1.09 to 3.76),
LVEF 50% (OR 2.49, 95% CI 1.30 to 4.74), final
coronary artery stenosis 30% (OR 2.57, 95% CI 1.28 to
5.15), coronary dissection on the final angiogram (OR 2.40,
95% CI 1.36 to 4.24), and intracoronary thrombus on the
Abbreviations and Acronyms
AMI  acute myocardial infarction
CK  creatinine kinase
I-TVR  ischemic target vessel revascularization
LVEF  left ventricular ejection fraction
PAMI  Primary Angioplasty in Acute Myocardial
Infarction
PCI  percutaneous coronary intervention
RE-MI  reinfarction
TIMI  Thrombolysis In Myocardial Infarction
Table 1. PAMI Database
Study
Years of
Enrollment
Included
(n  3,646)
% Reinfarction
(n  77)
PAMI-1 1989–1991 190 3 (1.6%)
PAMI-2 (randomized
and registry)
1991–1993 1,015 51 (5.0%)
PAMI Stent Pilot 1995–1996 309 5 (1.6%)
PAMI Local Med 1996 120 5 (4.2%)
Stent PAMI (randomized
and registry)
1997–1998 1,458 11 (0.8%)
PAMI NoSOS
(AirPAMI registry)
1996–1998 483 1 (0.2%)
AirPAMI (randomized to
transfer for PCI)
1997–1999 71 1 (1.4%)
PAMI  Primary Angioplasty in Myocardial Infarction; PAMI No SOS  PAMI
No Surgery On Site; PCI  percutaneous coronary intervention.
Figure 1. Reinfarction at 30 days.
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final angiogram (OR 2.36, 95% CI 1.23 to 4.53) (Fig. 2).
The percent of patients suffering RE-MI increases signifi-
cantly with an increasing number of independent risk
factors. Patients with zero risk factors had a one-month
RE-MI rate of 0.6% compared with a 22% incidence in
those with four risk factors.
The relation of RE-MI with six-month clinical outcomes.
Of the patients who had RE-MI, 16% died at six months
compared with 3% of those without RE-MI (p  0.0001).
Similarly, I-TVR during six-month follow-up was per-
formed in 54% of RE-MI patients and 9.1% of patients
without RE-MI (p  0.0001) (Fig. 3). Cumulative survival
of patients with RE-MI was significantly worse than pa-
tients without RE-MI (p  0.0001) (Fig. 4). Step-down,
multivariate, logistic regression analysis revealed that
RE-MI was a significant independent predictor of both
six-month I-TVR (OR 15.0, 95% CI 8.68 to 26.0) and
death (OR 7.14, 95% CI 3.28 to 15.5).
DISCUSSION
Early reinfarction after an AMI treated with primary PCI is
relatively uncommon. In our analysis, 2.1% of patients
suffered one-month RE-MI. This incidence is lower than
that reported in the several large, randomized AMI throm-
bolytic trials in the last 20 years, with in-hospital RE-MI
rates ranging from 2.5% to 4.3% (1,8,17), and one-month
RE-MI rate of 3.4% (18). Our incidence is also lower than
that seen in previous studies that included patients revascu-
larized by primary angioplasty. In Global Utilization of
Streptokinase and Tissue Plasminogen Activator in Oc-
Table 2. Baseline Clinical Characteristics of Patients With and
Without RE-MI
Variables
No RE-MI
(n  3,569)
RE-MI
(n  77) p Value
Age (mean  SD) 60.9  12 62.6  12 0.24
Women 959 (27%) 24 (31%) 0.40
Heart rate* 88  21 89  20 0.49
SBP* 111  26 112  24 0.84
Diabetes mellitus 592 (17%) 12 (16%) 0.81
Ever smoker 2,221 (65%) 37 (51%) 0.019
Prior myocardial
infarction
519 (15%) 11 (14%) 0.93
Prior angioplasty 353 (10%) 6 (8%) 0.53
Prior congestive heart
failure
87 (2.5%) 1 (1.4%) 1.00
Prior CABG 145 (4.5%) 5 (7.5%) 0.23
Peripheral vascular
disease
214 (6.2%) 6 (8%) 0.47
Hypertension 1,629 (46%) 37 (49%) 0.62
Hyperlipidemia 1,036/2,599 (40%) 29/66 (44%) 0.50
Stroke or TIA 185 (5.2%) 4 (5.3%) 1.00
Chronic obstructive lung
disease
105/2,089 (5%) 0/18 (0%) 1.00
Killip class on admission (n  3,526) Killip  1
1 3,064 (89%) 55 (74%) 0.0003
2 387 (11%) 19 (25%)
3 67 (1.9%) 2 (2.6%)
4 8 (0.2%) 0 (0%)
*Highest heart rate and lowest systolic blood pressure (SBP) recorded from presen-
tation to emergency room until arrival in the cath lab is shown here.
CABG  coronary artery bypass grafting; RE-MI  reinfarction; TIA 
transient-ischemic attack.
Table 3. Angiographic Characteristics
No RE-MI
(n  3,569)
RE-MI
(n  77)
p
Value
Pre-PCI variables
Ejection fraction 50% 61% 83% 0.0002
TIMI flow in culprit artery 0.039
0 62% 75%
1 11% 3%
2 16% 12%
3 11% 10%
Diameter stenosis in culprit
artery %
97  7 98  7 0.035
PCI variables
Infarct related artery location
RCA 42% 43% 0.95
LAD 41% 48% 0.24
LCX 14% 8% 0.12
Other* 6% 4%
Stent 35% 17% 0.0016
Abciximab 10% 1% 0.017
Post-PCI variables
TIMI flow in culprit artery 0.053
0 1% 4%
1 1% 0%
2 5% 9%
3 94% 87% 0.049
Diameter stenosis in culprit
artery %
15  17 28  24  0.0001
Thrombus† 10% 23% 0.0002
Dissection‡ 15% 31% 0.0005
PCI success§ 92% 81% 0.001
*Left main, saphenous vein graft, internal mammary artery, or unidentified; †In Stent
Primary Angioplasty in Acute Myocardial Infarction (PAMI) thrombus was defined
as post-PCI intraluminal filling defect or lucency surrounded by contrast material in
multiple projections, persistence of contrast material within the lumen, or visible
embolization of intraluminal material downstream. In PAMI-2 and PAMI No-SOS,
thrombus was defined as a filling defect at least half the vessel diameter, or if the vessel
remained occluded after PCI; ‡Dissection classified as post-PCI type 1 (grade A or
B dissection), type 2 (grade C dissection), or type 3 (grade D1, D2, E, F) post-PCI
coronary dissection; §PCI success was defined as TIMI 3 flow with final diameter
stenosis 50%.
LAD  left anterior descending artery; LCX  left circumflex artery; PCI 
percutaneous coronary intervention; RCA  right coronary artery; RE-MI 
reinfarction; TIMI  Thrombolysis In Myocardial Infarction.
Figure 2. Multivariate correlates of reinfarction (Re-MI).
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cluded Arteries (GUSTO) IIb, 30 day RE-MI occurred in
4.5% of patients (19). A meta-analysis of 23 randomized
trials conducted by Keeley et al. (11) reported that RE-MI
occurred in 3% of patients undergoing primary angioplasty.
Although our trial did not address a direct comparison of
PCI versus thrombolysis, prior literature has shown that
RE-MI occurs less frequently with primary PCI than it does
with thrombolytics (19). We found that most cases of
RE-MI occurred within four days of hospital admission.
Our study identified several independent determinants of
RE-MI (Fig. 1). Admission Killip class 1, LVEF 50%,
final coronary stenosis 30%, post-PCI coronary dissec-
tion, and post-PCI intracoronary thrombus were significant
predictors of one-month RE-MI. Unlike previous trials
(1,3–5,8,9,20), admission Killip class 1 was the only
clinical characteristic that identified patients at higher risk
of RE-MI. Rather, angiographic variables were the pre-
dominant predictors of one-month RE-MI. This is proba-
bly because previous studies had less detailed angiographic
data. The availability of such data in PAMI studies likely
overwhelms the predictive ability of clinical variables. Thus,
the occurrence of reinfarction is a function of poor angio-
graphic outcomes, and is less dependent upon clinical
factors identified in prior studies, such as age, gender, or a
history of diabetes.
Finally, we found RE-MI to be strongly associated with
increased mortality and revascularization at six months.
Those suffering one-month RE-MI had more than seven-
fold increased adjusted mortality at six months. Moreover,
the risk of I-TVR in RE-MI patients was 15-fold higher in
adjusted incidence. These findings are in accord with several
trials that all show strong associations between RE-MI and
death (1). This increased mortality underscores the need for
identification of high-risk patients, as well as effective
primary revascularization by PCI (4).
Implications. Angiographic predictors are stronger risk
factors for RE-MI than clinical factors; RE-MI may be
preventable by optimal coronary revascularization and treat-
ment of dissection and thrombus.
Summary. Reinfarction in the era of primary PCI for AMI
is rare, and less common then that reported previously. We
found one clinical characteristic and several angiographic
variables that are associated with higher RE-MI risk;
RE-MI, although infrequent, imparts a significantly higher
risk of future revascularization and death. Reinfarction may
be preventable, by optimal coronary revascularization and
aggressive treatment of post-PCI dissection and thrombus.
Study limitations. This study may suffer from bias related
to its retrospective analysis design. Our results cannot be
extrapolated to cardiogenic shock patients, as the PAMI
studies excluded these patients. Furthermore, our results
may be less representative of contemporary practice, due to
lower rates of glycoprotein IIb/IIIa and thienopyridine
medications, and lower stent use. The majority of RE-MI
cases occurred in PAMI II where balloon angioplasty
without stenting was the dominant treatment modality.
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